LLY Technical Analysis



As of date:3/27/2024
LLY stock price:778.18
LLY 50 DMA:727.40
LLY 200 DMA:589.25
LLY MACD (200-50):-138.15
LLY RSI:49.08
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)49.08
Extremely
Oversold

Also see:
LLY Market Cap History
LLY Shares Outstanding History
LLY YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree LLY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

MVB Financial Breaks Above 200-Day Moving Average - Bullish for MVBF
35 minutes ago


Bullish Two Hundred Day Moving Average Cross - MCBC
42 minutes ago


Bullish Two Hundred Day Moving Average Cross - JAKK
45 minutes ago


Monro (MNRO) Shares Cross Above 200 DMA
45 minutes ago


Bullish Two Hundred Day Moving Average Cross - EVRG
50 minutes ago


ONTF Crosses Above Key Moving Average Level
55 minutes ago


Life Time Group Holdings Breaks Above 200-Day Moving Average - Bullish for LTH
55 minutes ago


FTSM Crosses Below Key Moving Average Level
1 hour, 1 minute ago


HZO Crosses Above Key Moving Average Level
1 hour, 1 minute ago


Pan American Silver (PAAS) Shares Cross Above 200 DMA
1 hour, 1 minute ago


Ecopetrol Breaks Above 200-Day Moving Average - Bullish for EC
1 hour, 1 minute ago


GDXU Makes Bullish Cross Above Critical Moving Average
1 hour, 1 minute ago


DGX Makes Bullish Cross Above Critical Moving Average
1 hour, 5 minutes ago


WPP Breaks Above 200-Day Moving Average - Bullish for WPP
1 hour, 7 minutes ago


Essential Utilities (WTRG) Shares Cross Above 200 DMA
1 hour, 10 minutes ago


More Technical Analysis News

LLY Technical AnalysisLLY RSI
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

When researching a stock like Eli Lilly , many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from LLY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for LLY stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
LLY DMALLY MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Eli Lilly (LLY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

MCK Technical Analysis
MDT Technical Analysis
MMM Technical Analysis
MOH Technical Analysis
MRK Technical Analysis
MRNA Technical Analysis
PFE Technical Analysis
PODD Technical Analysis
REGN Technical Analysis
RMD Technical Analysis
More Healthcare companies »

 

LLY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2024, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.